Prostate Cancer Clinical Trials

This is a randomized, double-blind, placebo-controlled, multicenter phase III study. The study population will consist of approximately 1300 subjects with metastatic hormone sensitive prostate cancer (mHSPC), who will be randomized (1:1 ratio) to receive 600 mg (2 x 300 mg tablets) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to ...

The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer. For Study Locations, Click Here

The objective of this randomized phase III open label trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival compared to enzalutamide single agent in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. For Study Locations, Click Here

The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer. For Study Locations, Click Here

A Multi-Center, Open Label, Phase 2b study, Evaluating the safety, tolerability and efficacy of Targeted Intraprostatic Administration of XXXXX to treat men with histologically proven, clinically significant, localized, Low-to Intermediate-Risk Prostate Cancer that is associated with an MRI Leasion

Men with metastatic castration resistant prostate cancer are asked to participate in a research study being conducted by Montefiore Medical Center.

The ATR(ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas. The purpose of the proposed trial is to evaluate the safety and tolerability of BAY1895344, and to identify the maximum tolerated dose of BAY1895344 that could be safely given ...

The MR-guided ExAblate Focused Ultrasound study is being conducted to assess the safety and effectiveness of an investigational device for the treatment of prostate cancer. The ExAblate treatment is a focal treatment where a small portion of the prostate is treated, only where the cancer is located. The study will ...

Men with Prostate Cancer are asked to participate in a research study being conducted by Montefiore Medical Center.

A study for men diagnosed with early stage (localized) prostate cancer and are undergoing active surveillance (being observed over time to see if your prostate cancer changes). The purpose of this study is to see if enzalutamide, an approved product for treating prostate cancer in advanced stages, can delay the ...